SWM
RNTX

Spire Wealth Management’s Rein Therapeutics RNTX Stock Holding History

Spire Wealth Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-112
Closed -$1K – 2928
2021
Q4 		$1K Buy
+112
New +$1.73K ﹤0.01% 2907
2021
Q2 		– Sell
-112
Closed -$3K – 3013
2021
Q1 		$3K Buy
+112
New +$3.84K ﹤0.01% 2790

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

Spire Wealth Management's RNTX Position: Q1 2022 in Review

Spire Wealth Management sold out of Rein Therapeutics (RNTX) in Q1 2022, closing a stake of 112 shares — an estimated $1K sold.

Spire Wealth Management first reported a position in RNTX in Q1 2021 and held it in 2 quarters. The position peaked at $3K in Q1 2021. 42 funds tracked by Wall St. Rank hold RNTX as of Q1 2022.

  • Spire Wealth Management reported no remaining Rein Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 112 Rein Therapeutics shares in Q1 2022, an estimated $1K.
  • Spire Wealth Management first reported a position in Rein Therapeutics in Q1 2021 and held it in 2 quarters.
  • Spire Wealth Management's Rein Therapeutics position peaked at $3K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.